Montilab Chewable Tablet 5 mg

Montilab (Montelukast Sodium 5 mg) is a widely prescribed leukotriene receptor antagonist manufactured by Labaid Pharma Ltd. This chewable tablet helps manage asthma attacks, exercise-induced bronchoconstriction, and allergic rhinitis symptoms. Priced at ৳9.00 per unit, it offers cost-effective therapy with a strip price of ৳90.00 and pack size of 3×10 tablets for ৳270.00.

The drug works by blocking cysteinyl leukotriene receptors, reducing airway inflammation. Adults take 10 mg daily, while children’s doses range between 4-5 mg based on age. Storage requires cool, dry conditions below 30°C. Chewable tablets offer convenient administration with/without food.

Key indications include:

• Chronic asthma management and prevention
• Seasonal/perennial allergic rhinitis
• Exercise-induced breathing difficulties

Common side effects involve headache, nausea, and upper respiratory infections. Rare risks include neuropsychiatric symptoms like agitation or depression. Patients on warfarin or NSAIDs require monitoring, though major drug interactions are uncommon. Consult doctors before use during pregnancy/lactation.

As a budget-friendly alternative to pricier brands, Montilab 5 mg combines efficacy with Labaid Pharma’s quality standards. Its once-daily regimen improves adherence, making it a preferred choice for long-term respiratory care in Bangladesh.

Adults (15+ yrs): 10 mg once daily at bedtime. Children (6-14 yrs): 5 mg chewable tablet. For exercise-induced bronchoconstriction, take 2 hours before activity. Do not exceed recommended duration without medical supervision.

Common: Diarrhoea, fever, gastrointestinal discomfort, headache, nausea, vomiting, skin reactions, upper respiratory tract infection.

Uncommon: Akathisia, anxiety, arthralgia, asthenia, abnormal behavior, depression, dizziness, drowsiness, dry mouth, haemorrhage, irritability, malaise, muscle complaints, oedema, seizure, abnormal sensation, sleep disorders.

Rare: Angioedema, concentration impaired, disorientation, eosinophilic granulomatosis with polyangiitis, erythema nodosum, hallucination, hepatic disorders, memory loss, palpitations, pulmonary eosinophilia, suicidal tendencies, tremor.

Pregnancy Category B: Use only if benefits justify risks. Excreted in breast milk – caution during lactation.

Monitor neuropsychiatric symptoms (anxiety, depression). Not for acute asthma attacks – keep rescue inhalers. Periodic liver function tests recommended.

No dose adjustment needed in elderly or renal impairment. Hepatic impairment requires caution. Pediatric dosing based on age-specific guidelines.

There were no adverse experiences in the majority of overdosage reports. The most frequently occurring adverse experiences were consistent with the safety profile of Montilab and included abdominal pain, somnolence, thirst, headache, vomiting and psychomotor hyperactivity. In the event of overdose, it is reasonable to employ the usual supportive measures; e.g., remove unabsorbed material from the gastrointestinal tract, employ clinical monitoring, and institute supportive therapy, if required.